Lisata Therapeutics, Inc. (LSTA) Stock Analysis & Investment Frameworks

Lisata Therapeutics, Inc. (LSTA) stock analysis on Invetso. Review Lisata Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Lisata Therapeutics, Inc. Company Overview

Lisata Therapeutics, Inc. Key Financial Metrics

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

Lisata Therapeutics, Inc. Investment Frameworks

Invetso analyzes Lisata Therapeutics, Inc. (LSTA) across the following frameworks:

Explore More LSTA Research